Ultime notizie per Vir Biotechnology (NASDAQ:VIR) Azioni

Vir Biotechnology

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Vir Biotechnology Inc

Viratech Corp

Virco Manufacturing Corporation - Common Stock

Virco Manufacturing Corp

Pacer Funds Trust BioThreat Strategy ETF

Virtu Financial, Inc. - Class A Common Stock

Virtu Financial Inc

Viracta Therapeutics, Inc. - Common Stock

Viracta Therapeutics Inc

WIIM

PCTY

Paylocity Holding shares are trading higher after Truist Securities maintained a Buy rating on the stock and raised its price target from $195 to $210.

On Thursday,&nbsp;Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/earnings-beats/24/10/41655506/merck-beats-q3-estimates-but-lowers-annual-forecast-as-gardasil-vaccine-hit-by-low-c" rel="noreferrer noopener">consensus of $16.47 billion</a>.
Merck reported a decline of 11% in sales of Gardasil to $2.31 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., due to lower demand in China, partially offset by higher sales in the U.S., driven by public-sector buying patterns, higher pricing and demand, and higher demand in most international regions.
Beyond Gardasil, Goldman Sachs highlights a solid lineup of positives for Merck, including robust performance from key franchises like Keytruda and promising momentum from both commercial products like Winrevair and Capvaxive and development-stage innovations such as clesrovimab and tulisokobart.
Merck's blockbuster cancer immunotherapy Keytruda generated&nbsp;$7.43 billion&nbsp;in revenue during the quarter, up 17% from the year-earlier period.&nbsp;
The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37958211/mercks-11b-bet-pays-as-fda-approves-sotatercept-for-rare-lung-disease" rel="noreferrer noopener">sales of $149 million</a>.
Goldman reiterates the Buy rating for Merck stock, decreasing the price target from $139 to $135, reflecting lowered <a target="_blank" href="https://www.benzinga.com/quote/MRK/analyst-ratings" rel="noreferrer noopener">resetting of Gardasil forecasts</a>.
BMO Capital Markets suggests that Merck's Gardasil sales in China may continue to be challenging through 2025.
Although Merck does not provide specific product-level forecasts, CEO Rob Davis offered some perspective, anticipating Gardasil sales in China could reach around $2 billion to $3 billion in 2025.
Winrevair continues to show strong performance, driven by organic demand. According to a BMO analyst, there was some initial skepticism about the organic demand for Winrevair after comments regarding stocking in Q2 2024.
However, the recent performance data has restored confidence, indicating that the drug is experiencing sustained demand growth, with an uptake of approximately 80% for the quarter.
This trend is expected to continue into 2025, particularly with the forthcoming ZENITH and CADENCE trials.
BMO cut the price target from $150 to $136, with an Outperform rating.
Price Action: MRK stock is down 0.22% at $102.07&nbsp;at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41689161/wayfair-q3-results-earnings-beat-street-but-sales-and-customer-base-decline" target="_blank" rel="noreferrer noopener">Wayfair Q3 Results: Earnings Beat Street, But Sales And Customer Base Decline</a></li>
</ul>
Image via Merck

Analyst Color

Biotech

Large Cap

News

Health Care

Price Target

Analyst Ratings

Trading Ideas

General

Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease

TD Cowen analyst Jeffrey Osborne maintains Nikola (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) with a Hold and lowers the price target from $10 to $4.

NKLA

TD Cowen Maintains Hold on Nikola, Lowers Price Target to $4

Wells Fargo analyst Ken Gawrelski maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Underweight and lowers the price target from $47 to $44.

ETSY

Wells Fargo Maintains Underweight on Etsy, Lowers Price Target to $44

LECO

Lincoln Electric shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

TD Cowen analyst Jeffrey Osborne maintains Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) with a Buy and lowers the price target from $95 to $74.

APTV

TD Cowen Maintains Buy on Aptiv, Lowers Price Target to $74

Imperial Oil shares are trading lower after the company reported mixed Q3 financial results.

CTRA

Corterra Energy shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results and cut its FY24 capital expenditure.

B of A Securities analyst Bryan Spillane maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Neutral and lowers the price target from $100 to $75.

B of A Securities Maintains Neutral on Estee Lauder Cos, Lowers Price Target to $75

UBS analyst Jay Sole maintains Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) with a Buy and raises the price target from $103 to $110.

UBS Maintains Buy on Kontoor Brands, Raises Price Target to $110

Dayforce shares are trading higher after BMO Capital maintained an Outperform rating on the stock and raised its price target from $70 to $80.

Service Corp International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCI#NYSE">SCI</a>) reported better-than-expected third-quarter adjusted <a href="https://www.benzinga.com/quote/SCI/earnings">EPS results on Thursday</a>.
Service Corp Intl reported quarterly earnings of 79 cents per share beat the analyst consensus estimate of 77 cents per shsare. The company reported quarterly sales of $1.014 billion which missed the analyst consensus estimate of $1.016 billion.
Tom Ryan, the Company&#8217;s Chairman and CEO, commented, &#8220;Today we reported adjusted earnings per share of $0.79 and net cash provided by operating activities excluding special items of $269 million. We are excited to see the positive impact in funeral revenue from our new marketing agreement with our new preferred preneed insurance provider, which launched during the quarter. Additionally, we are pleased both funeral and cemetery gross profit were relatively stable versus the prior year third quarter with modest revenue growth reflecting our continued focus on managing fixed costs.&#8221;
Service Corp Intl said it sees fourth-quarter adjusted loss of $1.00-1.10 per share, versus estimates of 77 cents per share.
Service Corp International shares gained 0.2% to trade at $81.79 on Friday.
These analysts made changes to their price targets on Service Corp International following earnings announcement.
<ul>
<li>Raymond James analyst John Ransom maintained Service Corp Intl with an Outperform and increased the price target from $80 to $85.</li>
<li>Truist Securities analyst Tobey Sommer maintained the stock with a Buy and raised the price target from $84 to $92.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Earnings

Markets

Service Corp International Analysts Boost Their Forecasts After Upbeat Earnings

TD Cowen analyst Jeffrey Osborne maintains Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) with a Buy and raises the price target from $172 to $183.

GNRC

TD Cowen Maintains Buy on Generac Hldgs, Raises Price Target to $183

UBS analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $411 to $441.

MDGL

UBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $441

TD Cowen analyst Jeffrey Osborne maintains Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) with a Buy and raises the price target from $125 to $136.

ITRI

TD Cowen Maintains Buy on Itron, Raises Price Target to $136

Craig-Hallum analyst Anthony Stoss maintains Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) with a Buy and lowers the price target from $96 to $90.

SIMO

Craig-Hallum Maintains Buy on Silicon Motion Technology, Lowers Price Target to $90

On Thursday,&nbsp;Bristol Myers Squibb &amp; Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;posted third-quarter revenues of $11.89 billion, beating the consensus of $11.28 billion, an increase of 8% year-over-year, or 10% when adjusted for foreign exchange impacts, primarily driven by the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41655052/bristol-myers-squibb-boosts-2024-outlook-on-strong-demand-for-blood-thinner-med-new-drugs-drive-q" rel="noreferrer noopener">Growth Portfolio and&nbsp;Eliquis</a>.
Growth Portfolio worldwide revenues increased to $5.81 billion compared to $4.95&nbsp;billion a year ago, representing growth of 18% on a reported basis or 20% when adjusted for&nbsp;foreign exchange impacts.
BMO Capital Markets appreciates a conservative approach in the neuropsych space, though it notes management&#8217;s reserved stance on revenue expectations. It highlights that significant revenue is not expected until the second half of 2025, with a gradual launch anticipated for schizophrenia treatment.
The analyst considers the potential for Alzheimer&#8217;s psychosis treatment as an added upside, likely to positively impact sentiment.
While Bristol-Myers Squibb&#8217;s recent quarterly performance showed encouraging progress in top-line growth and cost management, its true transformation will stem from its pipeline, the BMO analyst writes.
The recent approval of Cobenfy, along with newly launched growth products, could bring the momentum investors have been anticipating.
Truist analysts noted that much of the Q3 earnings call centered on KarXT (Cobenfy), a critical asset for treating schizophrenia that could drive significant revenue and support long-term growth.
Truist analyst projects global peak sales at $4.2 billion, below the $5.4 billion consensus estimate.
While business development and partnerships are crucial to diversifying the company&#8217;s portfolio and strengthening its long-term outlook, Truist emphasized that maintaining dividends and reducing debt remain top priorities.
Price Action: BMY stock is down 1.91% at $54.71 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41686173/cancer-focused-essa-pharma-ends-prostate-cancer-trial-due-to-insufficient-efficacy-from-combinati" target="_blank" rel="noreferrer noopener">Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy</a></li>
</ul>
Image: Wikimedia Commons

Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious

Shares of Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) are trading lower Friday amid <a href="https://www.benzinga.com/markets/equities/24/11/41677355/trump-loses-1-9b-in-net-worth-as-djt-stock-tumbles-2nd-time-this-week">continued volatility</a> leading up to the 2024 U.S. presidential election.
What To Know: With the US elections approaching, Trump Media &amp; Technology Group's stock is experiencing volatility as it is closely tied to news about former President Trump and his prospects of winning.
According to S3 Partners, DJT shares surged in October as a short squeeze forced short sellers to cover positions. S3 predicts DJT could climb to $60 if Trump wins the election, but warns it could become "worthless" if he loses. Trading in DJT has been halted several times amid rapid price movements related to election developments.
What Else: <a href="https://nypost.com/2024/11/01/business/truth-social-stock-boom-fueled-by-chatter-of-possible-sale-to-elon-musk/">Commentary from the New York Post</a> this morning speculated Elon Musk may be considering a merger or acquisition of Truth Social through X (formerly Twitter). The Post has not confirmed this speculation. 
DJT Price Action: Trump Media and Technology shares were down 11.3% at $31.34 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-1024x530.png" alt="" class="wp-image-626033" style="width:519px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT.png 1480w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/startups/24/11/41691861/im-not-kidding-reddit-was-amazing-jim-cramer-compares-reddit-to-google-saying-choosing-between-them">&#8216;I&#8217;m Not Kidding, Reddit Was Amazing&#8217; — Jim Cramer Compares Reddit To Google, Saying Choosing Between Them Isn&#8217;t Easy</a></li>
</ul>
Image via Wikimedia Commons.

Movers

Trump Media & Technology Shares Are Dipping Today: What's Going On

UBS analyst Stephen Ju maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $223 to $230.

AMZN

UBS Maintains Buy on Amazon.com, Raises Price Target to $230

TD Cowen analyst Moshe Orenbuch maintains Credit Acceptance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CACC#NASDAQ">CACC</a>) with a Sell and lowers the price target from $400 to $380.

CACC

TD Cowen Maintains Sell on Credit Acceptance, Lowers Price Target to $380

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

Vir Biotechnology Q3 2024 Earnings Preview

Vir Biotechnology GAAP EPS of -$1.56 misses by $0.60, revenue of $2.38M misses by $3.13M

Reports Q revenue $2.4M, consensus $5.5M. "This quarter was transformational for Vir. We have bolstered our clinical pipeline with three potential ...

Vir Biotechnology reports Q3 EPS ($1.56), consensus ($1.05)

In a report released yesterday, Phil Nadeau from TD Cowen maintained a Buy rating on Vir Biotechnology (VIR – Research Report). The company's share...

TD Cowen Sticks to Its Buy Rating for Vir Biotechnology (VIR)

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Vir Biotechnology, Inc. ( ($VIR) ) has released its Q3 earnings. Here is a breakdown of the information Vir Biotechnology, Inc. presented to its in...

Vir Biotechnology Reports Q3 2024 Financial Results

U.S. drugmakers and biotechs rely on Chinese partners for manufacturing, research, and ingredients, but, with geopolitical tensions rising, compani...

U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vir Biotechnology (VIR – Research Report), Intra-C...

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Intra-Cellular Therapies (ITCI) and Neurocrine (NBIX)

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Vir Biotechnology (VIR – Research Report) today. The company's shares...

Bank of America Securities Sticks to Their Hold Rating for Vir Biotechnology (VIR)

ABUS

ALNY

ALPMF

ALPMY

ANTX

ATHA

AZNCF

BAYRY

BAYZF

BBIO

BMRN

CDTX

CRBU

CVAC

FGEN

FOLD

GLYC

HLVX

IBRX

INAB

ITCI

IVVD

KYMR

LXRX

NBIX

PGEN

QURE

RAPT

RHHBY

RLAY

RPTX

SLRN

VIRX

Press Releases

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Comments

Vir Biotechnology

Notizie

Ultime notizie per Vir Biotechnology (NASDAQ:VIR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO